176 related articles for article (PubMed ID: 15788883)
1. [HBV-specific CD8+ T cells for sustained HBeAg seroconversion after lamivudine therapy].
Lee CK; Han KH; Suh JH; Cho YS; Won SY; Chon CY; Moon YM; Park IS
Korean J Hepatol; 2005 Mar; 11(1):34-42. PubMed ID: 15788883
[TBL] [Abstract][Full Text] [Related]
2. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.
Yalçin K; Değertekin H; Kokoğlu OF; Ayaz C
Turk J Gastroenterol; 2004 Mar; 15(1):14-20. PubMed ID: 15264116
[TBL] [Abstract][Full Text] [Related]
3. The impact of HBV-DNA fluctuations on virus-specific CD8+ T cells in HBeAg+ chronic hepatitis B patients treated with a steroid and lamivudine.
Gotto J; Webster GJ; Brown D; Jenkins J; Dusheiko GM; Bertoletti A
J Viral Hepat; 2006 Jun; 13(6):415-25. PubMed ID: 16842445
[TBL] [Abstract][Full Text] [Related]
4. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.
Boni C; Penna A; Ogg GS; Bertoletti A; Pilli M; Cavallo C; Cavalli A; Urbani S; Boehme R; Panebianco R; Fiaccadori F; Ferrari C
Hepatology; 2001 Apr; 33(4):963-71. PubMed ID: 11283861
[TBL] [Abstract][Full Text] [Related]
5. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of lamivudine in patients with hepatitis B e antigen-negative chronic liver diseases].
Jeong Id; Park NH; Kim BC; Park JH; Seo KW; Kim DH; Joo KR; Kim DH
Taehan Kan Hakhoe Chi; 2003 Jun; 9(2):69-78. PubMed ID: 12824746
[TBL] [Abstract][Full Text] [Related]
7. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
8. Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression.
Yeh CT; Hsu CW; Chen YC; Liaw YF
J Clin Virol; 2009 Jun; 45(2):114-8. PubMed ID: 19451024
[TBL] [Abstract][Full Text] [Related]
9. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
Zhu M; Xu B; Yao GB
Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):534-6. PubMed ID: 16042894
[TBL] [Abstract][Full Text] [Related]
10. Intrahepatic CD8 T-lymphocytes and HBV core expression in relation to response to antiviral therapy for chronic hepatitis B patients.
Tang TJ; de Man RA; Kusters JG; Kwekkeboom J; Hop WC; van der Molen RG; Schalm SW; Janssen HL
J Med Virol; 2004 Feb; 72(2):215-22. PubMed ID: 14695662
[TBL] [Abstract][Full Text] [Related]
11. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion.
Fung J; Lai CL; Tanaka Y; Mizokami M; Yuen J; Wong DK; Yuen MF
Am J Gastroenterol; 2009 Aug; 104(8):1940-6; quiz 1947. PubMed ID: 19455108
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of lamivudine re-treatment and relapse patterns after initial lamivudine treatment for chronic hepatitis B infection].
Park JH; Park NH; Shin JW; Bang SJ; Kim DH; Joo KR; Kim DH
Taehan Kan Hakhoe Chi; 2003 Sep; 9(3):188-97. PubMed ID: 14515036
[TBL] [Abstract][Full Text] [Related]
14. [Direct analysis of HBV-specific CD8+ lymphocyte by tetrameric HLA-A2/core 18-27 complex in chronic Hepatitis B].
Lee CK; Suh JH; Cho YS; Han KH; Chung JB; Chon CY; Moon YM
Taehan Kan Hakhoe Chi; 2002 Jun; 8(2):139-48. PubMed ID: 12499799
[TBL] [Abstract][Full Text] [Related]
15. [Study of the relapse of patients with chronic hepatitis B undergoing first and repeated recombinant interferon-alpha therapy during long-term follow up].
Liu DL; Luo KX; Feng XR; Fu QX; Hou JL
Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(26):1840-3. PubMed ID: 17922996
[TBL] [Abstract][Full Text] [Related]
16. Determinants for sustained HBeAg response to lamivudine therapy.
Chien RN; Yeh CT; Tsai SL; Chu CM; Liaw YF
Hepatology; 2003 Nov; 38(5):1267-73. PubMed ID: 14578866
[TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of lamivudine re-treatment for relapsed patients after an initial lamivudine therapy in HBeAg-positive chronic hepatitis B.
Shin JW; Park NH; Park JH; Park JH; Jeong ID; Bang SJ; Joo KR; Kim DH
J Viral Hepat; 2005 Jul; 12(4):393-7. PubMed ID: 15985010
[TBL] [Abstract][Full Text] [Related]
19. Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan.
Chien RN; Liaw YF
Antivir Ther; 2006; 11(7):947-52. PubMed ID: 17302259
[TBL] [Abstract][Full Text] [Related]
20. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
Benhamou Y; Fleury H; Trimoulet P; Pellegrin I; Urbinelli R; Katlama C; Rozenbaum W; Le Teuff G; Trylesinski A; Piketty C;
Hepatology; 2006 Mar; 43(3):548-55. PubMed ID: 16496322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
